Solitomab

Solitomab (INN; development code MT110) is an artificial bispecific monoclonal antibody that is being investigated as an anti-cancer drug. It is a fusion protein consisting of two single-chain variable fragments (scFvs) of different antibodies on a single peptide chain of about 55 kilodaltons. One of the scFvs binds to T cells via the CD3 receptor, and the other to EpCAM as a tumor antigen against gastrointestinal, lung, and other cancers.^[1][2][3]

Solitomab

Monoclonal antibody
Type	Bi-specific T-cell engager
Source	Mouse
Target	EpCAM
Clinical data
ATC code	none
Identifiers
CAS Number	1005198-65-1
ChemSpider	none
UNII	ZQQ51B5708

Mechanism of action

A BiTE linking a T cell to a tumor cell.

Like other bispecific antibodies, and unlike ordinary monoclonal antibodies, solitumab forms a link between T cells and its target tumor cell antigen. This causes T cells to exert cytotoxic activity on tumor cells by producing proteins like perforin and granzymes, independently of the presence of MHC I or co-stimulatory molecules. These proteins enter tumor cells and initiate the cell's apoptosis.^[1][4] This action mimics physiological processes observed during T cell attacks against tumor cells.^[4]